anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Ruminal microbiota is gradually established after birth, while microbiota maturation could be highly diverse because of varied solid dietary accessibility. However, how the ruminal microbiota accreted from postnatal hay diets alters rumen epithelial development, and how this affects animal health remains largely unknown. Here, neonatal lambs were introduced to starchy corn-soybean starter or corn-soybean starter + alfalfa hay (AH) to investigate the influences of early life ruminal microbiome on rumen epithelial development using integrated 16s rRNA sequencing-metagenome-transcriptome approaches. The results showed that AH introduction elevated average daily weight gain, rumen weight and volume, rumen epithelial papillae length, and rumen muscle layer thickness. Meanwhile, the relative abundance of fibrolytic bacteria (Christensenellaceae R-7 group, Prevotellaceae UCG-001, and Succinivibrio), acetate producer (Acetitomaculum and Mitsuokella), and propionate producer Succiniclasticum was increased in the rumen content by AH supplementation (P < 0.05). Moreover, AH introduction decreased the relative abundance of total CAZymes, CBM, and GH and increased the abundance of KO genes related to volatile fatty acid (VFA) generation in the rumen content. AH lambs had a higher relative abundance of Succiniclasticum, Megasphaera, Succinivibrio, and Suttonella (P < 0.05), while a lower relative abundance of Cloacibacillus, Desulfovibrio, Dialister, Intestinimonas, Parabacteroides, and Pseudoscardovia (P < 0.05) in the rumen epithelial samples. Furthermore, these alterations in ruminal microbial structure and function resulted in ruminal epithelial cell proliferation and development pathways activation. In summary, AH introduction benefited ruminal fiber degradation and VFA generation bacteria colonization and promoted ruminal epithelial development. These findings provide new insights into ruminal microbial-host interactions in the early life.IMPORTANCEWhile it is established that a fiber-rich diet promotes rumen development in lambs, further research is needed to investigate the precise response of rumen microbiota and epithelium to high-quality alfalfa hay. Here, we observed that the inclusion of alfalfa hay led to a discernible alteration in the developmental trajectory of the rumen. Notably, there was a favorable shift in the rumen's volume, morphology, and the development of rumen papillae. Furthermore, ruminal microbial structure and function resulted in ruminal epithelial cell proliferation and development pathways activation, collectively provide compelling evidence supporting the capacity of alfalfa hay to enhance rumen development and health through ruminal micrbiota-host crosstalks. Our findings elucidate the functional response of the rumen to alfalfa hay introduction, providing new insights into strategies for promoting healthy development of the rumen in young ruminants.
Posttraumatic stress disorder (PTSD) is associated with alterations in arousal that do not respond well to evidence-based practices. Patients with PTSD tend to fall into one of two groups in extinction training (and in exposure therapy): 1) over-engagers, where arousal is too high; and 2) under-engagers, where patients are so worried about becoming upset that they distract themselves from the task (which prevents learning). In this mechanistic clinical trial, the investigators will evaluate a strategy to augment extinction training with neuromodulation to reduce arousal and improve extinction retention. Augmenting extinction training with continuous theta burst stimulation (cTBS, a type of transcranial magnetic stimulation) delivered to the intraparietal sulcus (IPS) may lead to targeted reductions in arousal. The investigative team has shown that the IPS is a "connectivity hub" for arousal and that stimulating this region with TMS can reduce excessive arousal in healthy people. The goal for this R01 is to evaluate the main effects of IPS cTBS (versus sham cTBS, a between-subject comparison) and its interaction with extinction training (vs. neutral training) on arousal among patients with PTSD. The investigators hypothesize that reducing parietal hyperexcitability will help patients with PTSD to modulate arousal during extinction training-enough arousal to ensure that they can benefit, but not too much arousal which prevents learning. These results could translate into future opportunities for novel therapeutic targets among patients with PTSD. The specific aims are as follows: Aim 1: To evaluate the optimal dose of IPS cTBS. H1: Attenuation of startle for IPS cTBS vs. sham cTBS will plateau at 1200 pulses, the anticipated optimal cumulative dose. Aim 2: To compare the main effect of IPS cTBS and its interaction with extinction training on arousal (measured by startle response). Using a two (between group: sham vs. IPS cTBS) x 2 (within group: extinction training vs. control/neutral training) randomized controlled design among patients with PTSD (N = 120), the investigators will examine the potential benefit of cTBS and extinction training on reduction in arousal. H2a: IPS cTBS will result in greater reduction in arousal compared to sham cTBS. H2b: Participants who receive IPS cTBS will have a significantly lower difference in retention of extinction learning vs. control/neutral training (indicative of greater retention of extinction learning) compared to participants who receive sham cTBS. Secondary: The investigators will test analogous hypotheses on subjective outcomes and on cognitive outcomes and the investigators hypothesize similar directions of effects. Aim 3: To evaluate neural mechanisms of action of IPS cTBS + extinction training. Participants will complete a resting state fMRI scan on tests of retention of learning experimental visits to evaluate neural changes from training. H3: The investigators will observe attenuated activation (relative to pre-test) of the IPS for participants who received IPS cTBS compared to those who received sham cTBS.
Meningococcal disease and gonorrhoea are caused by bacteria that are closely related but cause different diseases that are spread in different ways. New evidence suggests that the Meningococcal B vaccine (Bexsero®) licensed outside of Kenya against meningococcal B disease may also be effective against gonorrhoea due to genetic similarities between the two organisms causing the two diseases. Investigators will conduct a clinical trial of the Meningococcal B vaccine (Bexsero®) in approximately 50 male and female participants aged 18-25 years who are in follow up in KEMRI cohorts (including HIV-uninfected and infected individuals) at the KEMRI clinic in Mtwapa. This is not an efficacy trial. Instead, investigators will assess if immunisation of individuals at risk for gonococcal infection with 4CMenB (Bexsero®) elicits humoral and T cell cross-reactive responses against Neisseria gonorrhoeae (Ng). Participants will make six study visits, including a screening visit, an enrolment visit and 4 follow up visits. InvestigatorsF will offer vaccination with the Meningococcal B vaccine (Bexsero®) vaccine at the enrolment visit and approximately 2 months later. Investigators will collect a 20ml blood sample at enrolment, and following the first vaccination, and a 70ml blood sample following the second vaccination. At study completion (month 6), investigators will collect a 4ml blood sample. Investigators will collect a throat swab, a urine sample (for men), vaginal swab, and an anal swab at the enrolment, month 3 and month 6 visit to test for Chlamydiae and Gonorrhoea infection. Total study participation for participants is 6 months. Upon study completion, participants will continue to receive research care at the KEMRI clinic in Mtwapa.
A cleansing preparation adapted to be applied to the skin to remove grease &c. consists of a mineral oil, vegetable oil, petroleum jelly, or wool fat, together with less than 50 per cent of its weight of a mixture of a straight chain fatty alcohol having between twelve and eighteen carbon atoms with 10 per cent or less of its weight of an organic or inorganic salt of a sulphuric acid ester of such an alcohol, e.g. esters derived from oleyl, stearyl, or palmityl alcohols or mixtures thereof.  Grease solvents, e.g. cyclohexanol or methyl cyclohexanol, and antiseptics, e.g. b -naphthol or menthol, may be added.  In examples, a mixture of palmityl and stearyl alcohols containing 10 per cent of the sodium or triethanolamine salts of the sulphuric acid esters of these alcohols is mixed with medicinal paraffin, or with petroleum jelly, liquid paraffin, and zinc oxide. Specifications 341,979, [Group VI], 388,485, 436,956, and 448,350, [Group VI], are referred to.ALSO:A cleansing preparation adapted to be applied to the skin to remove grease &c. consists of a mineral oil, vegetable oil, petroleum jelly, or wool fat, together with less than 50 per cent of its weight of a mixture of a straight chain fatty alcohol having between twelve and eighteen carbon atoms with 10 per cent or less of its weight of an organic or inorganic salt of a sulphuric acid ester of such an alcohol, e.g. esters derived from oleyl, stearyl, or palmityl alcohols or mixtures thereof.  Grease solvents, e.g. cyclohexanol or methyl cyclohexanol, and antiseptics, e.g. b -naphthol or menthol, may be added.  In examples, a mixture of palmityl and stearyl alcohols containing 10 per cent of the sodium or triethanolamine salt of the sulphuric acid ester of these alcohols is mixed with medicinal paraffin, or with petroleum jelly, liquid paraffin and zinc oxide. Specifications 341,979; 388,485, 436,956, [both in Group III], and 448,350 are referred to.
Orthodontic articles and polymerizable resin compositions are described. The orthodontic article comprises a cured composition comprising the reaction product of free-radically polymerizable resin comprising 30 to 70 wt. %, inclusive, of at least one urethane component, and 25 to 70 wt. %, inclusive, of reactive diluent(s) comprising at least one monofunctional (meth)acrylate monomer. The polymerizable resin comprises no greater than 35 wt. % of reactive diluent(s) having a high affinity for water. Reactive diluent(s) such as monofunctional (meth)acrylate monomers having a high affinity for water have low log P values. In one embodiment, the polymerizable resin comprises at least one acidic monomer.
A system for emotional pattern matching is disclosed. The system includes at least a computing device, the computing device receives current user emotional activity data from a user. The computing device generates a user state classifier as a function of state training data, where the state training data comprises a plurality of elements of past user state emotional data. The computer device identifies a current user emotional state as a function of the user state classifier and the current user emotional state data, where the current user emotional state is a function of the emotional wellbeing of the user. The computing device matches the current user emotional state to a an emotional therapy. The computing device transmits the emotional therapy to a user. The A method for emotional pattern matching is also disclosed.
Forward head posture has been shown to be a common postural displacement, with a conservative estimate being 66% of the whole population. It is generally believed that this abnormal posture is associated with the development and persistence of many disorders. There are many strategies to treat forward head posture; the commonly used is traditional exercise program, which aims to restore muscle balance by stretching the short muscles and strengthening the weak ones. The second treatment method is Chiropractic BioPhysics (CBP) rehabilitation program which depend on stretching of the viscous and plastic elements of the longitudinal ligament and intervertebral disc, in addition to effectively stretching the soft tissue through the entire neck area in the direction of the normal head and neck postures as seen with Denneroll traction in addition to mirror image exercise. Up to our knowledge, there is no available studies evaluating the difference between the two forward head correcting methods regarding the amount of head posture correction and the impact of different correction methods on balance. Most important, in the majority of the previous studies which investigated the efficacy of the different posture correction techniques, the subjects were young people. Therefore, the results might not be applicable to all age groups, particularly to the elderly, due to age-related musculoskeletal and physiological changes. Accordingly, the aim of this study is to compare between traditional exercise program and chiropractic biophysics approach in elderly subject .
Delayed neurocognitive recovery (dNCR) is a common complication in geriatric surgical patients. The impact of anesthesia and surgery on patients with neurodegenerative diseases, such as Parkinson's disease (PD) or prion disease, has not yet been reported. In this study, we aimed to determine the association between a pre-existing A53T genetic background, which involves a PD-related point mutation, and the development of postoperative dNCR. We observed that partial hepatectomy induced hippocampus-dependent cognitive deficits in 5-month-old A53T transgenic mice, a model of early-stage PD without cognitive deficits, unlike in age-matched wild-type (WT) mice. We respectively examined molecular changes at 6 h, 1 day, and 2 days after partial hepatectomy and observed that cognitive changes were accompanied by weakened angiotensin-(1-7)/Mas receptor [Ang-(1-7)/MasR] axis, increased alpha-synuclein (α-syn) expression and phosphorylation, decreased methylated protein phosphatase-2A (Me-PP2A), and prompted microglia M1 polarization and neuronal apoptosis in the hippocampus at 1 day after surgery. Nevertheless, no changes in blood-brain barrier (BBB) integrity or plasma α-syn levels in either A53T or WT mice. Furthermore, intranasal administration of selective MasR agonist AVE 0991, reversed the mentioned cognitive deficits in A53T mice, enhanced MasR expression, reduced α-syn accumulation and phosphorylation, and attenuated microglia activation and apoptotic response. Our findings suggest that individuals with the A53T genetic background may be more susceptible to developing postoperative dNCR. This susceptibility could be linked to central α-syn accumulation mediated by the weakened Ang-(1-7)/MasR/methyl-PP2A signaling pathway in the hippocampus following surgery, independent of plasma α-syn level and BBB.
The hypothesis that CPX-351 treatment may be safe and efficacious in patients with newly diagnosed secondary AML comes from a single randomized Phase II study which observed significant improvement in survival in a 52-patient subset of patients with secondary AML. A Phase III confirmatory study has recently completed accrual and final results are not expected until mid-2016. Therefore, the sponsor has chosen to make CPX-351 available to secondary AML patients through this expanded access protocol until commercialization of CPX-351 or more information about the clinical utility is known.

This study is a Phase IV multicenter, single-arm open-label Expanded Access Protocol (EAP) of CPX-351 in patients with secondary acute myeloid leukemia who are suitable for treatment with intensive chemotherapy. Patients may receive up to two inductions and four consolidation courses. Patients will be monitored for safety (early deaths, serious adverse events, grade 3 and 4 adverse events, etc.) while on the study and for SAEs for 30 days after the last dose of CPX-351. Study enrollment will be available through commercialization of CPX-351.
Low back pain is very common; globally it is the number one cause of disability. National guidelines recommend exercise for the management of back pain; swimming is frequently advised despite little supporting evidence. Swimming is considered to be low impact and might target conditions associated with back pain such as obesity, inactivity, and depression. Swimming lessons are not funded by the NHS, many adults cannot swim and there are no guidelines regarding what type of swimming program to recommend.

This multi-phase mixed methods research project aims to develop a swimming class to be used as a form of rehabilitation for persistent low back pain. There are many barriers to exercise and this can affect uptake and adherence; Study 1 will be an online survey finding out what stops and what encourages people with back pain to go swimming. Some people already use swimming to manage back pain; in Study 2, individuals who use swimming to manage back pain will be interviewed to explore their experience including discussion about swimming stroke and adaptations. The swimming class will be developed in Study 3 using the data from Study 1 and 2 and by consulting physiotherapists, swimming teachers, and patients, through a series of surveys, known as the Delphi method. Study 4 will be a feasibility study; comparing the swimming class developed in Study 3 over 3 weeks to standard physiotherapy care. Data will be collected on the running of the study, outcomes including function and quality of life, with further follow up at on completion of the trial and 6 months. These studies will be carried out at East Kent Hospitals NHS Trust and the Hotel Burstin swimming pool; people with back pain for more than 3 months would be eligible to take part.
Treatment (hu14.18-Interleukin 2(IL2) fusion protein and isotretinoin). Patients receive sargramostim (SC \[preferred\]) or IV over 2 hours on days 1-2 and 8-14, hu14.18-IL2 fusion protein IV over 4 hours on days 4-6, and isotretinoin PO twice daily on days 11-24. Treatment repeats every 28 days for 4-10 courses in the absence of disease progression or unacceptable toxicity. Patients in stratum-1 who achieve stable disease (SD) after course 4 are removed from protocol therapy. Patients in stratum-2 who achieve SD after course 4 receive 2 additional courses of study treatment. Patients may undergo blood and bone marrow sample collection periodically for correlative studies.
N-Acetylcysteine supplementation: Orally, 40 mg/kg per day in 3 doses (250 ml each) for 7 consecutive days and immediately post-exercise. The remaining 8 days, 40mg/kg per day in 3 doses (250 ml each).
All CYP aged 8 years - 17 years \& 11 months whether they have had acute COVID-19 or not. Exposure to COVID-19 will be defined as a self-reported positive Sars-CoV-2 PCR test OR a positive self-reported OR self-reported presumed COVID-19 illness. Participants must have a recorded mobile number in their GP record.
PURPOSE:To obtain a sensitizer for the medicine sensitivity of a microorganism acquiring the resistance to an antibiotic substance, containing a polyphenol compound or a green tea extract as an active ingredient and usable especially in the field of chemotherapy of infectious diseases. CONSTITUTION:This sensitizer for the medicine sensitivity of a microorganism resistant to an antibiotic substance contains 0.01-99wt.% 10-50C polyphenol compound having 5-20 OH groups (e.g. epigallocatechin gallate) or an extract of green tea separated with water or an organic solvent (e.g. methyl alcohol) as an active ingredient. The polyphenol compound is excellent in suppressing actions on the manifestation or induction of the resistance of the microorganism to the antibiotic substance and has effects on sensitization of antibiotic sensitivity of the microorganism acquiring the resistance thereto by using thereof with the antibiotic substance. Escherichia coli, enterococci, Staphylococcus aureus, Pseudomonas aeruginosa, etc., are cited as the resistant microorganism and penicillin G, streptomycin, kanamycin, etc., are cited as the antibiotic substance. The active ingredient is prepared as a pharmaceutical preparation according to a conventional method and orally or parenterally administered in 1mg to 10g daily dose 1-4 times.
The increased remodeling of the extracellular matrix (ECM) in pulmonary fibrosis (PF) generates bioactive ECM fragments called matricryptins, which include elastin-derived peptides (EDPs). The interaction between EDPs and their receptors, including elastin-binding protein (EBP), plays a crucial role in exacerbating fibrosis. Here, we present LXJ-02 for the first time, a novel ultralong-acting inhibitor that disrupts the EDPs/EBP peptide-protein interaction, promoting macrophages to secrete matrix metalloproteinase-12 (MMP-12), and showing great promise as a stable peptide. MMP-12 has traditionally been implicated in promoting inflammation and fibrosis in various acute and chronic diseases. However, we reveal a novel role of LXJ-02 that activates the macrophage-MMP-12 axis to increase MMP-12 expression and degrade ECM components like elastin. This leads to the preventing of PF while also improving EDP-EBP interaction. LXJ-02 effectively reverses PF in mouse models with minimal side effects, holding great promise as an excellent therapeutic agent for lung fibrosis.
A mushroom fermentation dried powder medicament with antineoplastic activity takes mushroom C91-3 bacterial strain as raw material, which is alutaceous or golden ocher solid powder through submerged cultuse, filtering and freezing, and the pH value of water solution is 5.0-8.0. Instant granule, troche, capsule, oral liquid and the like can be made from the dried powder and adjunct. The experiment proves that the ratio of inhibiting tumor of H22 (little mouse ascites liver cancer cell strain), U14 (little mouse ascites uterine neck cell strain) and S180 (little mouse ascites caruncle cell strain) to the fermentation of the medicament after seventy-two hours is separately 71.11%, 72.85% and 76.81% in the external and antineoplastic test. The invention has the action of curing the caruncle in the internal and antineoplastic test. The tumor bearing mice cure rate of H22 is 35%, the tumor bearing mice cure rate of S180 is 40% with obvious action of inhibition tumor. Animal toxic experiment proves that the invention has safety and reliability without the toxic.
The present invention comprises methods of treating disorders associated with vascular injury from mechanical stimuli including restenosis, atherosclerosis and reperfusion injury. In one embodiment of the invention gene therapy techniques are applied using genes encoding a variety of proteins that play key roles in transducing an extracellular signal through to the nucleus including src, Ras, MEKK and JNK. These proteins are mutated such that they are rendered signal transduction incompetent, thus abrogating their ability to induce a cellular response. The invention further encompasses viral gene therapy vectors containing genes encoding these signaling incompetent mutants and pharmaceutical compositions. Additional embodiments of the invention encompass alternative means of inhibiting the key signal transduction pathways related to mechanical injury. One alternative includes the use of antisense versions of genes encoding key proteins such as src, Ras, MEKK, JNK and the like. Chemical compounds acting as enzymatic inhibitors or disrupters of protein:protein interactions are also contemplated by the present invention.